The Role of Tumor Mutational Burden in Lung Cancer

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Goeffrey Oxnard and Lauren Ritterhouse discuss the need for validation and standardization of Tumor Mutational Burden to make it a robust biomarker, in conjunction with PD-L1, in selecting immunotherapy for their lung cancer patients.

Related Videos

July 29, 2015

Assessing the Value of Cancer Treatments

Dr. Steve O’Day believes a treatment’s value incorporates combination of benefits, side-effects, and cost, stating that if the cost is high, we need to make sure the benefits are huge as well.

January 4, 2017

Serotonin and Carcinoid Tumors

Hal Gerstein, MD, details this neurotransmitter’s role in the development of carcinoid tumors and carcinoid syndrome.